Method of obtaining peptides

专利摘要:
Human pancreatic GRF analogs which are extremely potent in stimulating the release of pituitary GH in mammals and which have the formula: H-R-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-R15-Gln-Leu-Se r-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-R27-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn- Gln-Glu-Arg-Gly-Ala-Y wherein R is selected from the D- and L-isomers of Tyr, Phe and His, R15 is Gly or D-Ala, R27 is selected from the group consisting of the D- and L-isomers of Ala, Nle, Ile, Leu, Met and Val, and Y signifies the carboxyl moiety of the amino acid residue at the C-terminal and is the radical -COOR1,-CR1O,-CONHNHR1,-CON(R1)(R2) or -CH2OR1, with R1 and R2 being lower alkyl or hydrogen, provided that when R is Tyr, R27 is other than Met. Phe may be substituted for Tyr in the 10-position, and D-Ala may be substituted for Gly in the 28-position. These peptides or biologically active fragments thereof, which will generally extend from the N-terminal to the vicinity of a residue between positions 27 and 32, as well as nontoxic salts of any of the foregoing, may be administered therapeutically to animals, including humans, and may be used diagnostically.
公开号:SU1575944A3
申请号:SU864027688
申请日:1986-06-23
公开日:1990-06-30
发明作者:Эдуард Фредерик Ривьер Жан；Валкер Вэйл Вили (Младший)；Шписс Иохим
申请人:Дзе Салк Институт Фор Биолоджикал Стадиз (Фирма)；
IPC主号:

专利说明:

The invention relates to a method for producing peptides - analogues of hp human GRF, new biologically active compounds that can be used in medicine.
The purpose of the invention is a method for producing new peptides-analogues of hp human GRF, low-toxic, with a high growth-promoting activity.
Abbreviations used in the description:
DCC-N, N - dicyclohexylcarbodiimide; HOBt - 1-hydroxybenztriazole; ONp - p-nitrophenyl; Voy - tertbutyloxycarbonyl; Tos is 4-toluenesulfonyl; 2C1-Z-2-chlorobenzyloxycarbonyl;
DCB is 2,6-dichlorobenzyl; OBzl - benzyl ester,

cm
Example 1. Synthesis of Nle2TJ - hp, GRF / 1-32 / -NH 9 having the formula
11-Tyr-Ala-Asp-Ala-Tle-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-t Ser-Ala-ArR-Lysr-Leu-Leu-Gln -Asp-Ile-Nle Ser-Ar.f5-Gln-Gln-Gly-NH2, is carried out stepwise using a Beckman-990 peptide synthesizer, on an MBHA hydrochloride resin, such as, for example, jg zaou, a mixture of 50% dimethylformeO0, 5 ,
CHjCl (twice) 0.5
Thus, from 1 to 2 mmol of Boc-protected amino acid in methylene chloride is used per gram of resin in combination with one equivalent of 1.0 M DCC1 in methylene chloride for 2 hours. When Boc-Arg (TOS) is a resin supplied by Bachem, The having a substitution range of 0.1 to 0.5 mmol / g resin. The binding of Boc-Gly to the resin is carried out in the manner described in programs A and B, which is used throughout the synthesis, which leads to the replacement of approximately 0.35 mmol of glycine per gram of resin. All solvents used are carefulness of methylene chloride. Benzyl ester is used as a hydroxyl protecting group of the side chain for serine and threonine. The para-nitrophenyl ester (ONp) is used to activate the carboxyl end of asnatine or glycine, for example, Boc-Asn. (ONp) is bound overnight using one equivalent of HOBt
Zau, use a mixture of 50% dimethylforMeON0, 5,
CHjCl (twice) 0.5
Thus, from 1 to 2 mmol of Boc-protected amino acid in methylene chloride is used per gram of resin in combination with one equivalent of 1.0 M DCC1 in methylene chloride for 2 hours. When Boc-Arg (TOS) is bonded and methylene chloride. Benzyl ester is used as a hydroxyl protecting group of the side chain for serine and threonine. The para-nitrophenyl ester (ONp) is used to activate the carboxyl end of asnatine or glycine, for example, Boc-Asn. (ONp) is bound overnight using one equivalent of HOBt
but it is outgassed by flushing inert- 20 to 50% mixture of dimethylformamide and chloris30
with a gas, such as helium or nitrogen, to ensure the absence of oxygen, which can oxidize the sulfur Osatka methionine, which is undesirable.
After removal of protection and neutralization, the peptide chain is staggered on the resin. Deprotection, neutralization and addition of each amino acid are carried out according to the programs formulated below.
Removal of protection is preferable to implement the program A. Program A
Reagent Mixing Time
min
60% trifluoroacetic acid / 2% ethanedithiol 60% trifluoroacetic acid. acid / 2% ethanedithiol 1PA / 1% ethanedithiol EtjN (10%) in CH2Cl2 Me OH
Et9N (10%) in MeOH (twice) CH2Cl7 (twice)
Binding is preferable to be carried out under program B. Program B
ten
15 0.5 0.5 0.5
0.5 0.5 0.5
35
40
50

Mixing time, min
50-90 0.5 0.5
15.0 0.5
0
five
five
0
0
five
addition of methylene, in which case no DCC is added. The amino group of asnatine and glutamine is protected by xanthyl, if DCC binding is used instead of using the active ester, 2-chlorobenzyloxycarbonyl (2C-Z) is used as a protecting group for the lysine side chain. To protect the guanidino group of arginine, tosyl5 is used, and the carboxyl group of glycine or asparagine is protected with benzyl ester (OBzl) „the phenolic hydroxyl group of tyrosine is protected with the aid of 2,6-dichlorobenzyl (DCB). At the end of the synthesis, the following composition is obtained;
X-Tug (X-Ala-Asp (X t) -Ala-Ile-Phe- -Thr (X3) -Asn (Xff) -Ser ((X4) - -Ag (X 1 g) -Lys (X,) -Val Leu-Gly-Gln (X) - -Leu-Se r (X3) -Ala-Arg (X,) - Lys (X /) -, .., -Leu-Leu-Gln (Xj -) - Asp (X) -Ile-Nle- -Ser (X3) -Arg (X) -Gln (Xs) -Gln (Xs.) - -Gly-Xp where X is Boc X 1 is tosyl, X4 is benzyl ester (OBzl) s X3 - benzyl X - dichlorobenzyl 5 X g - xantilel Hy - 2-chlorobenz-yloxycarbonyl and X 7 - -NH-Podgodka Resin Xanthyl can be partially or completely removed by treatment with trifluoroacetic acid used to remove the of-amine protective group about
After tyrosine residue is bound to the resin, Voye is removed with 60% trifluoroacetic acid in CH2C1 g. To break up and remove protection from the remaining protected peptide-resin, it is treated with 15 5 ml of anisole, 0.5 ml of methyl ethyl sulfide and 15 ml of hydrogen fluoride . (Hf) on
gram of peptide resin at -20 ° C for 1 - 0.5 h and at 0 ° C for 1 - 0.5 h. After removing HF under high vacuum, the residue of resin-peptide is washed alternately with anhydrous diethyl ether and chloroform, and then the peptide is extracted with degassed 2N. acetic acid solution and separated from the mixture by filtration.
The cleaved and deprotected peptide is dissolved in 0.5% acetic acid and purified, which may include a fine gel filtration on Sephadex DG-50.
Then the peptide is subjected to further purification using preparative or semi-preparative high performance liquid chromatography. Sleeves for Le-500 from Waters Associates are filled with 15-20 µm silica, supplied by Vydac (300A). The acetonitrile gradient is created using an Eldex low pressure gradient apparatus. The chromatographic fractions are carefully controlled by high performance liquid chromatography and only fractions exhibiting a significant frequency are combined. The desalting of the purified fractions independently tested for purity is carried out using acetonitrile in 0.1% trifluoroacetic acid. The final elution is carried out from a Vydal Cf analytical column (5 microns) using a mixture of buffers A and B. Buffer A is 0.1% aqueous trifluoro-acetic acid, buffer B contains 60% by volume of acetonitrile, 0 , 1% trifluoro-acetic acid, the rest is E-iQ. For an isocratic mixture containing 58% by volume of buffer B, the peptide is eluted at 9.2 ml. The central section is lyophilized to obtain the desired peptide, the purity of which is above 98%.
Optical rotation is measured on a photoelectric field, as the value of C ° P -57.8 ° ± 1 (, 1% acetic acid, uncorrected).
Example 2. Synthesis of hp GRF analogue of D-Tyri} -hp GRF (1-32) -NH2, having the formula HD-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys -Val-Leu- -Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu- -Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln- -Gln-Gly-NH, is conducted stepwise, using the Beck peptide synthesizer
o
five
0
five
0
man-990, on the MBHA resin according to the method described in Example 1. The purity of the peptide is determined by thin layer chromatography and high performance liquid chromatography by elution from a column at 8.6 ml using 60 vol.% buffer B. Optical rotation measured on a photoelectric field as an oP value, 4 ° i1 (, 1% acetic acid, uncorrected). PRI me R 3. Synthesis of CD-Met 27J-hp GRF (1-32) -NH, having the formula H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn- -Ser-Tyr- Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-H-MeL-Ser-Arg-Gln-Gln-Gly-NH, performed stepwise using the Beckmann-990 peptide synthesizer on the MBHA resin according to the method described in Example 1. The purity of the peptide is determined by thin layer chromatography and high performance liquid chromatography eluted from the column at 7.6 ml using 57% buffer B. Optical rotation is measured by a photoelectric field as the value fo -54.5 ° ± -1 (, 1% acetic acid, several recited).
PRI me R 4. Synthesis of Gys1J-hp GRF (1-32) -NHi, having the formula H-His-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-r -Arg- Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-NH-i, is carried out stepwise using a Beckmann-990 peptide synthesizer on an MBHA resin according to the method described in Example 1. The purity of the peptide is determined by thin layer chromatography and high performance liquid chromatography, eluted from the column at 9.0 ml using 54% buffer B. Optical the rotation is measured on a photoelectric field, as Ul LQ -58.70i1 (, 1% acetic acid, uncorrected tirovano).
The synthesis is repeated using His as the last residue to obtain (HisVhp GRF (1-32) -NH2. The purity of the peptide is determined by elution from the column at 9.2 ml using 58% buffer B. on the photoelectric polarimeter, as the value of -58, (, 1% acetic acid, unadjusted).
0
five
0
five
Example Synthesis of Gvs1, NleiTj-hp GRF (1-32) -NHj, having the formula, H-His-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu- Gly-Gln-Leu-5-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-Gln-Gln-Gly-NH2, performed stepwise using the Beckmann-990 peptide synthesizer , on the MBHA resin according to the method described in Example 1. The purity of the peptide is determined by thin layer chromatography and high performance liquid chromatography, eluted from a column with
9.6 ml using 57% buffer B. 15 after injection. Hormone content
Optical rotation is measured on a photoelectric field, as -59, (, 1% acetic acid, uncorrected).
Synthetic peptides obtained in various examples are compared with purified synthetic hp GRF (1-40) -OH or with purified synthetic hp GRF (1-40) -Phen-Gly-Sh2 in in vitro assays to determine their effectiveness as a stimulus growth hormone secretion hormones. All of these synthetic analogues have significant efficacy in stimulating hormone growth.
In vitro assays were performed using synthetic hp GRF as a standard, in parallel comparison with equimolar concentrations of various synthesized analogs. Cultures containing rat pituitary gland cells removed four to five days before are used. Cultures that are considered optimal for isolating growth hormone are used for comparative testing in a general manner. Incubation with the test substance is carried out for 3-4 hours, aliquots of the culture medium are removed and processed to measure the content of immunoreaction growth hormone (ir GH) in them by a known method of radioimmunoassay
The results of the comparative test using equimolar concentrations are given in the table.
An in vitro test of synthetic peptides indicates that the effective EC concentration varies from 20 to 100 pM. The lowest effective concentration is 3-8 pM. The maximum effective day hp concentration of GRF (1-40) NH.j was 1 nM
In addition to in vitro tests, in vivo experiments have been carried out by injecting a synthetic peptide through a permanent catheter into freely moving male normal mice. Animals are pretreated with FLA-63 dopamine hydroxylase inhibitor, which suppresses spontaneous release, growth hormone ,; no effect on the response to exogenous hormonal excretory factor (GRF). Blood samples are taken through the same catheter before administration, after 5 and 20 minutes.
0
five
five
0
Q
five
0
five
growth in blood is measured by radioimmunoassay.
The results show that synthetic analogs are strong stimulators of the release of pituitary growth hormone.
In in vitro tests, the GRF 1 2 compound is somewhat weaker than the corresponding natural hormone. In Ln vivo tests, it exhibits a biological effect on the release of growth hormone, which is significantly higher than the effect of the corresponding hormone with an unsubstituted 32 residue, as well as a higher standard.
Tests carried out showed that the compounds of the invention are low toxic and exhibit a high growth rate of the lyre activity.

权利要求:
Claims (1)
[1]
Invention Formula
The method of producing peptides of the general formula
HR1-Ala - Asp Ala Ile-Phe-Thr-Astt-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-, -Ser-Ala-Arg-Lys-Leu-Leu-Gln- Asp-Ile-R in-Ser-Arg-Gln-Gln-Gly-NHis where R is Tyr, D-Tyr or Hisj
R 17 - Nle, Met,
characterized in that the C-terminal amino acid, glycine with a protected amino group, is bound to the carrier polymer — MBHA resin in a ratio of 2 mmol of amino acid per gram of resin, in methylene chloride, or cimethylformamide, or in a mixture of them and carry out a gradual increase in peptide chains in accordance with the target peptide to form a peptidyl polymer of the general formula
XR, (X 1 or X4) -Ala-Asp (Xj-Ala-Ile-Phe-Thr (X3) -Asn (X f) -Ser (X 3) -Tyr (X4) Arg (X,) - Lys (X-Val-Leu-Gly-Gln (X) (X3) -Ala-Arg (Xp- -Lys (X ") -Leu-Leu-Gin (Xj) -Asp (X2) -Ile- -Rz7-Ser (X3) -Arg (X) -Gln ((X5.) - -Gly (Xp,
where R1 and K17 have the indicated values X - Baugh;
X. t tosil;
Xj.- OBzl;
X3 is benzyl;
X - dichlorobenzyl;
the biological activity of the peptides described
Peptide
tNle77 -hp GRF (1-32) -NH7 Hislj-hp GRF (1-32) -NHt D-Tyr -hp GRA (t-32) -NH2 His I, Nle27J-hp GRF (t-32) -NH4
Note: Relative to hp GRF (1-40)
Xj - xanthyl;
X6 is 2-chlorobenzyloxycarbonyl;
X7 is a carrier resin of MVHA, and the resulting peptidyl-polymer is unblocked and the peptide is cleaved with -HF together with an acceptor, such as anisole, methyl ethyl sulfide, or their mixture at a temperature of 0 - (- 20) ° C, followed by dissolution in acetic acid and cleaning.
Relative efficacy in vitro
3.21 (2.02-5.43) 2.15 (1.12-4.41) 0.74 (0.47-1.14) 3.22 (2.12-5.33)
-Phe-Gln-NH
g

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1575944A3|1990-06-30|Method of obtaining peptides

---

SU1426455A3|1988-09-23|Method of producing peptides

---

FI88402B|1993-01-29|FREQUENCY ANALOGUE FREQUENCY ANALOGUE

---

SU1530097A3|1989-12-15|Method of producing peptides

---

SU1477248A3|1989-04-30|Method of producing peptides

---

RU2095368C1|1997-11-10|Cyclic peptides or their pharmaceutically acceptable salts, a method of their synthesis

---

CZ281507B6|1996-10-16|Synthetic peptides, biologically active fragment and said peptide non-toxic salts

---

KR0138907B1|1998-04-30|Synthetic peptides

---

EP0117034B1|1988-08-31|Grf analogs

---

EP0363589A2|1990-04-18|Somatostatin analogues

---

PT94553A|1991-02-08|PROCESS FOR THE PREPARATION OF NEW ANALOGOS II OF VASOACTIVE INTESTINAL PEPTIDES | AND OF PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM

---

PT87529B|1992-09-30|PROCESS FOR THE PREPARATION OF GROWTH HORMONE LIBERTACAO FACTOR ANALOGS VII |

---

CA1243301A|1988-10-18|Crf and analogs

---

KR0163033B1|1998-11-16|Grf analogs viia

---

CA1247599A|1988-12-28|Mammalian pgrf

---

CA1304193C|1992-06-23|Grf analogs v

---

Miranda et al.1993|Synthesis of human CCK26-33 and CCK-33 related analogs on 2, 4-DMBHA and TMBHA

---

Caranikas et al.1982|Synthesis and biological activities of substance P antagonists

---

CA1340964C|2000-04-18|Crf analogs

---

US4703035A|1987-10-27|Human pancreatic GRF amidated fragments

---

AU593973B2|1990-02-22|Grf analogs v

---

CZ3004U1|1995-03-03|Peptides and pharmaceutical compositions containing them

同族专利:

---

公开号 | 公开日

---

NZ206578A|1987-06-30|

---

ZA839629B|1984-08-29|

---

CA1271898A|1990-07-17|

---

US4529595A|1985-07-16|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

RU2646885C1|2017-02-15|2018-03-12|Владимир Николаевич Коваль|Oligopeptide composition|

---

US4728726A|1982-10-04|1988-03-01|The Salk Institute For Biological Studies|GRF analogs IIIb|

---

US4732972A|1983-03-07|1988-03-22|Hoffmann-La Roche Inc.|Polypeptides having growth hormone releasing activity|

---

US5416073A|1983-08-10|1995-05-16|The Adminstrators Of The Tulane Educational Fund|Growth hormone-releasing peptides and method of treating animals, therewith|

---

US4617149A|1983-09-21|1986-10-14|Eli Lilly And Company|Growth hormone release factor analogs|

---

US4747825A|1984-06-29|1988-05-31|Ferring Laboratories, Inc.|Apparatus and methodology for pulsed administration of growth promoting agents|

---

FR2567524B1|1984-07-10|1987-11-27|Sanofi Sa|PROCESS FOR THE SYNTHESIS OF SOMATOCRININ IN LIQUID PHASE AND INTERMEDIATE PEPTIDES|

---

US4622312A|1984-09-24|1986-11-11|Hoffmann-La Roche Inc.|Growth hormone releasing factor analogs|

---

US4649131A|1984-09-24|1987-03-10|Hoffmann-La Roche Inc.|Growth hormone releasing factor analogs|

---

US4734399A|1985-08-06|1988-03-29|Hoffmann-La Roche Inc.|Growth hormone releasing factor analogs|

---

US4689318A|1985-08-29|1987-08-25|The Salk Institute For Biological Studies|GRF analogs|

---

US4710382A|1985-09-27|1987-12-01|Recker Robert R|Treatment for osteoporosis using hGRFNH2|

---

US4880778A|1986-05-12|1989-11-14|Eastman Kodak Company|Combinations having synergistic growth hormone releasing activity and methods for use thereof|

---

US4839344A|1987-06-12|1989-06-13|Eastman Kodak Company|Polypeptide compounds having growth hormone releasing activity|

---

US4801456A|1987-07-09|1989-01-31|International Minerals & Chemical Corp.|Growth hormone-releasing factor analogs|

---

USRE33699E|1987-07-09|1991-09-24|International Minerals & Chemical Corp.|Growth hormone-releasing factor analogs|

---

US4880777A|1987-09-01|1989-11-14|Eastman Kodak Company|Synthetic peptides having growth hormone releasing activity|

---

EP0400051B1|1988-01-28|1995-05-10|Polygen Holding Corporation|Polypeptide compounds having growth hormone releasing activity|

---

DE3906074C2|1989-02-27|1991-02-14|Walter Dr. 7914 Pfaffenhofen De Schmid|

---

US5756458A|1989-06-16|1998-05-26|Pharmacia & Upjohn Company|Stabilized potent GRF analogs|

---

AU656144B2|1990-06-29|1995-01-27|F. Hoffmann-La Roche Ag|Histidine substituted growth hormone releasing factor analogs|

---

DE69108192T2|1990-12-10|1995-07-20|Hoffmann La Roche|Process for the enzymatic production of GRFNH2.|

---

JPH05507939A|1991-04-09|1993-11-11|

---

US5246920A|1992-06-15|1993-09-21|University Of South Florida|Treatment of hyperprolactinemia|

---

US5811074A|1992-06-29|1998-09-22|University Of South Florida|Method of diagnosing pituitary dependent growth hormone deficiency|

---

US7268113B2|2001-02-02|2007-09-11|Conjuchem Biotechnologies Inc.|Long lasting growth hormone releasing factor derivatives|

---

US20060128615A1|2002-09-18|2006-06-15|Pierrette Gaudreau|Ghrh analogues|

---

US20090088380A1|2007-07-12|2009-04-02|Pierrette Gaudreau|Ghrh analogs and therapeutic uses thereof|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/457,862|US4529595A|1983-01-13|1983-01-13|GRF Analogs|

---